Sustainability at Biocon

Novels: Pipeline Progress made in Q4FY22 KEY HIGHLIGHTS Biocon 1 Pivotal Phase III clinical study of Itolizumab for aGVHD* initiated in March 2022 Bicara* initiated dose expansion cohorts evaluating BCA101 in patients with head and neck, anal canal & cutaneous squamous cell carcinoma 10 *Acute Graft-Versus-Host Disease #In Q4FY21, Biocon ceded control over the Board of Directors and Operations of Bicara Therapeutics Inc. to enable it to operate independently under a US based leadership team and raise funds to advance its development programs. As a result of this change, Bicara was classified as an Associate from a Subsidiary under IND-AS. 25

View entire presentation